Merck is acquiring VelosBio for $2.75 billion
… Merck builds oncology business with purchase of VelosBio…

Merck Announces $2.75 Billion Acquisition of VelosBio

Surprise deal will bolster Merck’s oncology business enterprise

VelosBio has a unique focus on oncology product development

Merck is assertively transforming their organization

  • Announcing the formation of a new spinoff company based on a major corporate divestiture of certain brand, legacy product and biosimiliar business franchises
  • Sale of their StayWell business unit to WebMD/Internet Brands
  • Entering the global battle against COVID-19 by investing in the development of an antiviral drug and 2 vaccine products (which includes the acquisition of Themis Bioscience)
  • Achieving significant progress in an oncology collaboration in the development of a prostate cancer tandem therapy with their Keytruda (pembrolizumab) drug and Seattle Genetics’ Padcev(enfortumab vedotin-ejfv) therapy
  • Successfully launching two new oncology therapies, Koselugo (selemetinib)and Lynparaza (olaparib) in partnership with Astra Zeneca
  • Participating in a recent venture with Sanofi that focuses on a potential oncology tandem therapy consisting of Keytruda (pembrolizumab) and Sanofi’s pipeline candidate THOR-707